Transcutaneous trans-aortic valve replacement (TAVR) is now a common procedure to treat symptomatic aortic stenosis. Although as effective and safe as surgical aortic valve replacement, it is still restricted to high surgical risk patient who are frail. The aim of the TAVI-EVA is to identify geriatric biomarkers that may help to predict survival and functional recovery after TAVR
Primary objective: identify geriatric biomarkers associated with vital/functional status after TAVR. Primary outcome measure is altered functional status at six month follow-up defined as an absolute decrease of 15 points of the Barthel Index. Secondary outcome measures are: Barthel index and survival at 6, 9 and 12 months follow-up. QOL during follow-up
Study Type
OBSERVATIONAL
Enrollment
515
Percutaneous aortic valve replacement
Institut de Cardiologie-GH Pitié Salpétirère
Paris, Île-de-France Region, France
Maintaining or improving the level of functional independence, defined as a score of Barthel index at 6 months
Time frame: at 6 months
Score of Barthel
Maintaining of the same Score
Time frame: at 6, 9 and 12 months
Maintain or improve the quality of life score at 6 months, defined as a score of SF-12 scale at 6 months
Time frame: at 6 months
Survival rate at 6 months, 9 months, 12 months
Time frame: at 6, 9 and 12 months
Survival time after TAVI during the study
Time frame: up to 30 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.